. Bi-allelic mutations in ERCC4
have been linked to Xeroderma Pigmetosum (XP [MIM 278700; 610651; 278720; 278730; 278740; 278760; 278780; 278750] ) (Sijbers, et al., 1996) and progeria (XFE [MIM 610965]) (Niedernhofer, et al., 2006) diseases. Very recently, it has been published that bi-allelic mutations in the gene are also causative of disease in previously unclassified Fanconi Anemia (FA) patients subtype FA-Q and, therefore, the use of FANCQ as an alias for ERCC4 was approved by the HUGO Gene Nomenclature
Committee . Individuals harbouring mutations in ERCC4 show high variability on their clinical manifestations, ranging from mild XP symptoms (sun sensitivity, freckling of the skin and basal or squamous cell carcinomas) to the dramatic accelerated aging symptoms of a progeroid syndrome, and finally, as recently shown in FA patients, to malformations and progressive bone marrow failure. It has been also demonstrated that a balance between NER and ICLR activities due to different effects caused by distinct mutations in ERCC4 determined the final clinical outcome . On the other hand, given that FA-Q patients are normal in FANCD2 monoubiquitination, it has been suggested that mono-allelic mutations in ERCC4 could be linked to the breast and ovarian hereditary cancer syndrome as it occurs with other FA genes such as BRCA2/FAND1 (Howlett, et al., 2002) , BRIP1/FANCJ (Seal, et al., 2006) , PALB2/FANCN (Rahman, et al., 2007) and RAD51C/FANCO (Meindl, et al., 2010; Osorio, et al., 2012) (Romero, et al., 2011; Fernandez-Rodriguez, et al., 2012; Osorio, et al., 2012; Bonache, et al., 2013) . We identified five and four unique variants among cases and controls among which three and four respectively were considered as putatively deleterious. Missense mutations were evaluated using the program CONDEL that predicts the pathogenicity of non synonymous variants using a consensus deleteriousness score that combines various tools such as SIFT, Polyphen2 and MutationAssessor (http://bg.upf.edu/condel/home).
Those missense variants predicted to be deleterious by CONDEL were considered as predicted to affect protein function and this was studied later by functional analysis; those predicted to be neutral were considered as such and not further evaluated (Table 1) .
Regarding cases, one of the mutations found, c.584+1G>A in intron 3, was confirmed to cause skipping of exon 3 of the gene and a premature stop codon (PTC) (data not shown).
The other two mutations, p.Arg150Cys in exon 3 and p.Ser786Phe in exon 11 were later functionally investigated. Regarding controls, we identified two different frameshift mutations c.540_541delAG in exon 3 (found in two independent controls) and c.2291delG in exon 11, both predicted to cause PTCs. Even though this later PTC is very C-terminal and could potentially result in a shorter but partially functional protein, this mutation results in a truncated XPF protein that lacks the double helix-hairpin-helix (HhH2) domain involved in heterodimerization with ERCC1 and DNA binding (de Laat, et al., 1998) , very similar to a pathogenic ERCC4 mutation (c.2371_2398dup28; p.Ile800Thrfs*24) that functionally disrupts NER and ICLR activities . The last deleterious variant found in controls was the missense p.Arg689Ser in exon 11 previously found in a FA patient, and demonstrated to cause abnormal nuclease activity and to specifically disrupt ICLR . No differences were found regarding localization of mutations in the gene among cases and controls (Table 1 ).
All variants reported have been submitted to the Leiden Open Variation Database (LOVD).
To evaluate the functional impact of the missense variants, we cloned a-HA-tagged WT ERCC4 cDNA in a pBABE-puro retroviral vector (Addgene plasmid 14430, kindly shared by Dr. LM Martins) in IRES with the GFP cDNA, and the c.448C>T, c.2065C>A
and c.2357C>T variants were introduced by site directed mutagenesis . The resulting constructs were transduced in NER and ICLR deficient Ercc4 KO mouse embryonic fibroblasts (MEFs) and, after puromicin selection, the green cells were sorted to achieve a purity of over 98% by FACS . Due to the bicistronic nature of the IRES construct, we were able to assess the stability of the mutant XPF proteins using GFP as a reference, since both proteins are encoded by the same mRNA (Pelletier and Sonenberg, 1988) . The p.Arg689Ser variant reduced by 40% the stability of XPF, while the p.Arg150Cys and p.Ser786Phe variants had no impact on protein stability (Fig. 1A and 1B) . UVC sensitivity of Xpf KO MEFs was complemented with the expression of both p.Arg150Cys-and p.Ser786Phe-XPF (Fig. 1C) , and only the Xpf KO MEFs expressing p.Ser786Phe-XPF or p.Arg689Ser showed a FA phenotype in terms of mitomycin C (MMC) sensitivity (Fig. 1D) , MMC-induced cell cycle arrest at the G2/M phase ( Fig. 1E ) and DEB-induced chromosome fragility (Fig. 1F ). These data confirms that, resembling p.Arg689Ser, p.Ser786Phe specifically disrupts ICLR and, therefore, is a bone-fide FA mutation. Interestingly, both mutations are located in the nuclease domain of XPF. Despite a mild MMC sensitivity ( Fig. 1D and 1E ), Ercc4 KO MEFs expressing p.Arg150Cys-XPF did not show DEB-induced chromosome fragility (Fig 1F) . These data, together with the protein stability and UVC sensitivity data, indicate a null impact of the c.448C>T variant on XPF NER functions and a mild effect on ICLR activity.
In conclusion, the frequency of 
